Podcasts about Imaging

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter explores the critical topic of breast cancer screening, examining why thousands of women continue to die from breast cancer each year despite the availability of effective screening tools. He explains the strengths and limitations of current screening strategies, reviews the recommendations from major medical organizations, and discusses why screening guidance can often seem confusing or contradictory. Peter outlines a practical framework for understanding breast cancer risk and personalizing screening decisions, including when to begin screening, how frequently to screen, and which imaging modalities may be most appropriate based on an individual's risk profile. Throughout the episode, he emphasizes that while population-based guidelines provide an important foundation, optimizing outcomes requires a more personalized approach aimed at helping women make informed screening decisions that can improve the chances of early detection and successful treatment. We discuss: Why women still die from breast cancer: the benefits of screening, the problem of under-screening, and the need for risk-based screening strategies [1:45]; Current screening recommendations, why they differ between organizations, and the importance of personalized screening decisions [6:30]; A framework for personalizing screening [8:45]; Assessing baseline breast cancer risk: genetics, family history, breast density, lifestyle factors, and the role of risk calculators in personalized screening [9:30]; Balancing cancer detection and false positives: how breast cancer risk influences screening intensity and imaging choices [17:45]; Mammography as the foundation of breast cancer screening: detecting ductal carcinoma in situ (DCIS) and the advantages of 3D versus 2D mammography [21:00]; MRI for high-risk women: the benefits of supplemental screening, abbreviated MRI, and the emerging role of contrast-enhanced mammography [23:00]; The role of ultrasound: supplemental cancer detection, diagnostic evaluation, and limitations compared with mammography and MRI [26:00]; Choosing the right breast cancer screening strategy: imaging modality selection, screening hierarchies, and the importance of imaging center quality [28:00]; How often should you screen for breast cancer? [30:15]; At what age should you start screening? [37:30]; Breast cancer in younger women: aggressive tumor biology, BRCA-related risk, breast density, and individualized decisions about when to begin screening [41:45]; Inflammatory breast cancer, the limitations of screening mammography for symptomatic disease, and the importance of promptly evaluating new breast symptoms in both women and men [44:45]; From risk assessment to personalized screening: a practical framework for reducing breast cancer mortality through earlier and more effective detection [46:30]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

From IV therapies to PET scans and detox strategies, Dr. Josh shares what works in clinical settings to reverse dementia symptoms. #DementiaReversal #BrainDetox #NeuroImaging #FunctionalMedicine

  A Chiropractor's Road to Ghana: Dr. Craig Slapinski on Travel, Spinal Decompression, and Finding Your Path Episode Sponsor This episode of Conversations with a Chiropractor is supported by Lemongrove Oil. Visit Lemongrove Oil and use coupon code DRSTEPHANIE at checkout to save 10% on your next order. This offer is exclusive to Conversations with a Chiropractor listeners. Lemongrove Oil: https://www.lemongroveoil.com/ Episode Description In this episode of Conversations with a Chiropractor, Dr. Stephanie Wautier sits down with Dr. Craig Slapinski, a chiropractor and former Palmer College classmate whose career has taken him from the Midwest to Ghana, Nigeria, and beyond. Dr. Craig shares how a love of travel shaped his life long before chiropractic school. From building houses in Mexico as a teenager to studying abroad in London, backpacking through Europe, exploring China, and traveling through Southeast Asia, his path has always included curiosity, adventure, and a willingness to step into unfamiliar places. That same spirit eventually led him to Ghana after chiropractic school, where he worked in a high-volume clinic and quickly learned how to trust his hands, sharpen his adjusting skills, and serve patients with limited equipment and a lot of real-world pressure. Years later, he returned to West Africa with a more focused mission: to bring nonsurgical spinal decompression care to communities where access to this type of treatment was limited. Stephanie and Dr. Craig talk about chiropractic in Ghana and Nigeria, what makes the healthcare experience different from the United States, and how his clinics use spinal decompression, cold laser, exercise, ergonomics, and rehabilitation to help patients dealing with disc-related back pain. This conversation is also about finding your own path. Dr. Craig's story is a reminder that a chiropractic career can take many shapes, and that sometimes the road you end up on is not the one you planned, but the one that fits who you are becoming. This episode is meant to inform and inspire, not replace personal medical advice. If you are dealing with back pain, disc issues, sciatica, or considering surgery, please work with a qualified healthcare professional who can evaluate your individual situation. In This Episode, Discover How Dr. Craig Slapinski and Dr. Stephanie Wautier met at Palmer College of Chiropractic Dr. Craig's early love of international travel What he learned from traveling through Mexico, Europe, China, Thailand, Laos, and Cambodia How a planned move to China turned into an unexpected opportunity in Ghana What it was like practicing chiropractic in Ghana right out of school How high-volume care helped Dr. Craig sharpen his adjusting skills How he became interested in nonsurgical spinal decompression What spinal decompression is designed to do for disc-related back pain Why some patients may explore decompression before considering surgery How Dr. Craig combines decompression, cold laser, exercise, and ergonomics Why he returned to Ghana and eventually expanded into Nigeria The differences between insurance-driven care in the United States and cash-based care in Africa What healthcare access, MRIs, and patient education can look like in Ghana and Nigeria How Dr. Craig's clinics serve patients across West Africa Why chiropractic careers can take many different paths Stay Connected & Explore Learn More About Dr. Craig Slapinski: To learn more about Dr. Craig's work in West Africa, search: Spine and Nerve Center Ghana Spine and Nerve Center Nigeria Episode Sponsor: Lemongrove Oil: https://www.lemongroveoil.com/ Use coupon code DRSTEPHANIE at checkout for 10% off. Connect with Conversations with a Chiropractor: Follow Us on YouTube: http://www.youtube.com/@ConversationswithaChiro Follow Dr. Stephanie on Facebook: https://www.facebook.com/wautierwellness Email for show-related inquiries and sponsorships: drstephaniewautier@yahoo.com Want to be a guest on Conversations with a Chiropractor? Send Stephanie Wautier a message on PodMatch, here: https://www.podmatch.com/hostdetailpreview/drstephanie Credits Podcast production by Brand|Sound. Start your podcast journey by emailing brandsoundpodcasts@gmail.com. Chapters 00:00 Introduction to Conversations with a Chiropractor 01:00 Meet Dr. Craig Slapinski 01:19 A Love of Travel Begins 02:41 Backpacking Through Southeast Asia 03:31 Navigating Different Cultures and Languages 04:35 From a China Plan to a Ghana Opportunity 05:07 Practicing Chiropractic in Ghana 06:31 Building Confidence as a Chiropractor 07:11 Returning to the US and Discovering Decompression 08:00 Lemongrove Oil Sponsor Message 09:52 What Nonsurgical Spinal Decompression Does 11:10 Disc Pain, Surgery, and Other Options 12:08 Bringing Decompression Back to Ghana 13:03 Opening Clinics in Ghana and Nigeria 15:05 Building a Team Across West Africa 15:47 Chiropractic Training and Practice in Africa 16:40 Chiropractic, Insurance, and Patient Choice 18:17 Caring for a Wide Range of Patients 19:00 Food and Culture in Ghana 20:16 Educating Patients Across Languages 21:15 Staffing and Patient Care in the Clinics 22:00 MRIs, Cost, and Access to Imaging 23:09 What Treatment Looks Like 25:00 Is Decompression Comfortable? 25:54 Results With Decompression Care 26:40 How to Find Dr. Craig Slapinski 27:23 Finding Your Path in Chiropractic 28:00 Closing Thoughts 28:37 Lemongrove Oil Sponsor Message

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/the-evolving-role-of-antibody-drug-conjugates-in-metastatic-triple-negative-breast-cancer-10800SummaryThis CME/CE-certified podcast will provide multidisciplinary clinicians with an evidence-based update on the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline treatment of metastatic triple-negative breast cancer. A medical and an ocular oncology specialist review the latest efficacy and safety data from pivotal clinical trials evaluating ADCs, their integration into contemporary treatment algorithms, and guideline recommendations based on PD-L1 status, BRCA mutation status, and immunotherapy eligibility. Learners will explore key factors influencing treatment selection, compare the benefits and limitations of more established therapeutic options, and examine practical strategies for preventing, recognizing, and managing ADC-associated toxicities. Special emphasis will be placed on multidisciplinary approaches to the management of ocular adverse events and other clinically significant toxicities to optimize patient outcomes and support safe implementation of these therapies in clinical practice.Learning ObjectivesEvaluate the current and emerging clinical evidence surrounding the use of trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugates (ADCs) in the first-line treatment of metastatic triple-negative breast cancer (TNBC)Integrate TROP2-directed ADCs into frontline treatment regimens for metastatic TNBC based on the latest clinical evidence, guidelines, and patient- and tumor-specific factorsApply multidisciplinary and patient-centric strategies for the prevention, recognition, and management of toxicities associated with the use of TROP2-directed ADCs in patients with metastatic TNBCThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Faculty and Moderator Aditya Bardia, MDProgram Director, Breast Medical Oncology, UCLAProfessor of Medicine, UCLALos Angeles, CADr. Bardia has disclosed the following financial relationships:Consultant: Alyssum, AstraZeneca/Daiichi, BMS, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeAdvisor/Advisory Board: Alyssum, AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeContracted Research: AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, PfizerStock options: Vyome (immuno-inflammatory and rare diseases)All of his consultant, advisor/advisory board, and contracted research disclosures are related to cancer.Maura Di Nicola, MDAssistant Professor of OphthalmologyBascom Palmer Eye InstituteMedical Director of Imaging and EchographyBascom Palmer Eye InstituteMiami, FLDr. Di Nicola has disclosed the following financial relationships:Consultant: AbbVie (ophthalmology), SpringWorks Therapeutics (oncology)Advisor/Advisory Board: AbbVie (ophthalmology)Research Grant: Castle Biosciences (ocular oncology)Please review additional planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by a medical education grant from AstraZeneca Pharmaceuticals and a medical education grant from Daiichi Sankyo, Inc.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

How do you feel about mammograms?  Have you had one?  More than one?  Or, are you feeling guilty or reckless for not getting one yet?  Conventional medical dogma is definitely to get regular mammograms.  Mammograms are our first line of defense against breast cancer.   You probably personally know someone who has encouraged you to get a mammogram because a mammogram discovered cancer in them or someone they love, and they want to make sure you're taking care of your health by getting screened before it's too late.  We're very indoctrinated that mammograms save lives.  Too bad they don't.https://auria.care/science  coupon code: drjenn20U.S.  QT imaging locations: https://www.qtimaging.com/locations/ Dr Jenn Simmons' Podcast episodes:11,  34,  64,  96,  125,  142,  144Cochrane report on mammographic screeningBoobs: The War on Breasts Documentary by Megan SmithArticle in the Journal of the Royal Society of Medicine to an article called “Mammography Screening is Harmful and Should be Abandoned.”Are you ready to give your cells their best chance to not have to stop living before they die by allowing them access to physiologic levels of hormones, but aren't sure how to even get started?  Join the waitlist for my new beta program here and help me figure out how best to help wonderful women like you get the hormone care they deserve!Join the Waitlist HereCome visit me: www.healthcouragecollective.comemail me: healthcouragecollective@gmail.com

AI in Imaging: How Will it Change What We Do   Guest: Tim Poterucha, M.D. Host: Kyle Klarich, M.D.   Artificial intelligence (AI) is beginning to reshape how we acquire, interpret, and act on cardiovascular imaging, particularly echocardiography. In this episode, we'll walk through how we got here—from the historical innovation arc of echo to modern AI tools that segment images, detect disease, and support interpretation—and discuss what is real, what is hype, and where the true clinical opportunities and risks lie. We'll also explore what this means for practicing clinicians and trainees who are considering a future in imaging.   Topics Discussed: When it comes specifically to cardiovascular imaging, what is the current role of AI, and why is imaging such a natural fit for these tools? What are the problems with how we interpret imaging now, and what are the risks of AI? What is hype right now, and what is real? Is AI going to replace cardiologists for medical imaging interpretation, and should cardiology fellows be worried about going into imaging with the rise of AI?   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode.   Podcast episode transcript found here.   Recorded 01-December-2025

A 25-year-old pregnant woman presents with a 1-day history of progressive pain and swelling. The foot is cold, pulseless and neurologic function is deteriorating by the hour. Imaging shows a massive iliofemoral DVT. Now both the limb and the pregnancy are threatened. Do you anticoagulate, thrombolyse or operate? Join us as we break down the management and decision making behind this rare but devastating case.Hosts:·      Christian Hadeed -PGY 4 General Surgery, Brookdale Hospital Medical Center·      Paul Haser -Division Chief, Vascular Surgery, Brookdale Hospital Medical Center·      Andrew Harrington, Vascular surgery, Brookdale Hospital Medical Center·      Lucio Flores, Vascular surgery, Brookdale Hospital Medical CenterLearning objectives:-       Recognize the clinical presentation and pathophysiology of phlegmasia cerulea dolens-       Describe how pregnancy affects decision making in patients with phlegmasia and venous thromboembolic disease-       Discuss the goals of treatment for patients with DVT's and identify when operative intervention is indicated-       Describe the sequelae of DVT's and how this relates to post thrombotic syndrome-       Review the indications, risks, and limitations of anticoagulation, catheter-directed thrombolysis, thrombectomy, and fasciotomy in the management of DVT and phlegmasia.-       Explain the role of IVUS in managing venous thromboembolic disease and May Thurner syndromeReferences:-       Vedantham, S., Goldhaber, S. Z., Julian, J. A., Kahn, S. R., Jaff, M. R., Cohen, D. J., Magnuson, E., Razavi, M. K., Comerota, A. J., Gornik, H. L., Murphy, T. P., Lewis, L., Duncan, J. R., Nieters, P., Derfler, M. C., Filion, M., Gu, C.-S., Kee, S., Schneider, J., … Kearon, C. (2017). Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. New England Journal of Medicine, 377(23), 2240–2252. https://doi.org/10.1056/NEJMoa1615066-       Gomes, M. S., Guimarães, M., & Montenegro, N. (2019). Thrombolysis in pregnancy: A literature review. Journal of Maternal-Fetal & Neonatal Medicine, 32(14), 2418–2428. https://doi.org/10.1080/14767058.2018.1438402-       Mangla, A., & Hamad, H. (2023). May-Thurner syndrome. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554377/-       Bates, S. M., Rajasekhar, A., Middeldorp, S., McLintock, C., Rodger, M. A., James, A. H., et al. (2018). American Society of Hematology 2018 guidelines for management of venous thromboembolism: Venous thromboembolism in the context of pregnancy. Blood Advances, 2(22), 3317–3359. https://doi.org/10.1182/bloodadvances.2018024802-       Kahn, S. R., Comerota, A. J., Cushman, M., Evans, N. S., Ginsberg, J. S., Goldenberg, N. A., et al. (2014). The postthrombotic syndrome: Evidence-based prevention, diagnosis, and treatment strategies. Circulation, 130(18), 1636–1661. https://doi.org/10.1161/CIR.0000000000000130 https://pubmed.ncbi.nlm.nih.gov/25246013/Sponsor URL: https://www.goremedical.com/If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Neurosurgeon Christina Jackson, MD, and radiation-oncologist Emily Lebow, MD, discuss the treatment of meningiomas, tumors of the meninges renowned for their tendency to recur following resection, andreview the tools used to image (DOTATATE-PET), target (Lutathera), and destroy (GammaTile) residual meningioma cells to prevent recurrence of the disease.

Imaging in Subclinical Psoriatic Arthritis CAR-T For Rheumatoid Arthritis This Is a Woman's World: Women's Health in Rheumatic Disease Dietary Interventions in PsA

Dr. Julie Chen, Chief Medical Officer at Radence, outlines the use of genomic precision medicine and advanced biomarkers and imaging technology for early detection and diagnosis of disease, with a focus on extending the health span, not just the lifespan, of their clients.  This comprehensive membership-based model aggregates members' health data to create a 360° view of their health risks. AI is a critical tool for identifying trends in longitudinal data, enabling more accurate and personalized health monitoring for both those who are healthy and those recovering from an existing condition. Julie explains, "Our model is a membership-based model primarily because a lot of the leading-edge technology is not insurance-covered. And so we're able to then utilize what is necessary for the diagnosis and the management, and actionable steps for the members, without having to worry about what insurance will or will not cover." "Our members come through, and we actually aggregate all of their outside medical records and data because we want to see what their baseline health has been up to the point that they join us as a member. And then at that point, we actually get from the cellular level all the way up to the organ level and functionality level, we start to aggregate information about their genomics, so the blueprint of who they are health-wise."   "The key focus here is really looking at the concept that longevity is a larger picture phrase that has been in this industry, used across the board for a lot of different things. That could encompass biohacking, to true evidence-based genomic precision medicine, to just trends of what people are using. So I think it's really important for your listeners to understand that longevity is theoretically in the category of what we're doing in that space, but the very important point is to really look at the space, as there are a lot of things on the market now."   #Radence #GenomicMedicine #PrecisionMedicine #EarlyDetection #HealthSpan #Longevity #AIinHealthcare #PreventiveCare  Radence.com Listen to the podcast here

Dr. Julie Chen, Chief Medical Officer at Radence, outlines the use of genomic precision medicine and advanced biomarkers and imaging technology for early detection and diagnosis of disease, with a focus on extending the health span, not just the lifespan, of their clients.  This comprehensive membership-based model aggregates members' health data to create a 360° view of their health risks. AI is a critical tool for identifying trends in longitudinal data, enabling more accurate and personalized health monitoring for both those who are healthy and those recovering from an existing condition. Julie explains, "Our model is a membership-based model primarily because a lot of the leading-edge technology is not insurance-covered. And so we're able to then utilize what is necessary for the diagnosis and the management, and actionable steps for the members, without having to worry about what insurance will or will not cover." "Our members come through, and we actually aggregate all of their outside medical records and data because we want to see what their baseline health has been up to the point that they join us as a member. And then at that point, we actually get from the cellular level all the way up to the organ level and functionality level, we start to aggregate information about their genomics, so the blueprint of who they are health-wise."   "The key focus here is really looking at the concept that longevity is a larger picture phrase that has been in this industry, used across the board for a lot of different things. That could encompass biohacking, to true evidence-based genomic precision medicine, to just trends of what people are using. So I think it's really important for your listeners to understand that longevity is theoretically in the category of what we're doing in that space, but the very important point is to really look at the space, as there are a lot of things on the market now."   #Radence #GenomicMedicine #PrecisionMedicine #EarlyDetection #HealthSpan #Longevity #AIinHealthcare #PreventiveCare  Radence.com Download the transcript here

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Spencer Behr discusses PSMA PET and functional imaging. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41557]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Spencer Behr discusses PSMA PET and functional imaging. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41557]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Spencer Behr discusses PSMA PET and functional imaging. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41557]

Contemporary OB-GYN Ultrasound 2026 - Hybrid Event, will be held in Gaylord Rockies Resort & Convention Center, Aurora, CO on September 18-20, 2026 World Class CME City: Charlotte Address: 6201 Fairview Rd. Website: https://worldclasscme.com/

   ✨ Agena Astro |

May 31, 2026 / Sunday Sermon: Imaging the Trinity / Fr. Ryan Jordan by Trinity Episcopal Church Vero Beach

Full article: Human-in-the-Loop Large Language Model–Augmented Diagnostic Reasoning in Thoracic Imaging: Impact of Radiologic Expertise Use of LLMs in the diagnostic reasoning process can either improve or hinder performance. Pranjal Rai, MD, discusses the AJR article by Song et al. exploring the association of reader expertise and reader performance when using LLMs as a diagnostic aid.

Equipping Hour | Imaging God in a Broken World | Sex and Gender (1) by OrlandoGrace

https://www.contrast-connect.com/blog-post/cms-direct-supervision-definition-requirementsUnderstand the CMS rule that came into effect in January 2026 and learn what it means, how to implement compliant workflows, and how the rule improves operational efficiency and patient access. ContrastConnect City: Las Vegas Address: Las vegas Website: https://www.contrast-connect.com/

Multi-site imaging networks face complex budget forecasting when adopting virtual contrast supervision. Learn how to map cost centers, apply three-layer comparisons, and unlock up to seventy percent savings—all while staying CMS-compliant and audit-ready. Read more at https://www.contrast-connect.com/blog-post/virtual-contrast-supervision-budget-forecasting-for-multi-site-networks ContrastConnect City: Las Vegas Address: Las vegas Website: https://www.contrast-connect.com/

Hey Guys!Happy weekend :)

This week we review a recent report from the team at Amrita Institute in Cocchin, India about their use of extended reality and virtual reality as well as heart model printing to aid in planning for complex intracardiac baffles for the treatment of complex congenital heart defects. What was the process used to provide actionable advice in the operating room during surgery? How has the team in southern India created a workflow that can accurately predict this complex anatomy and the patches needed to successfully septate complex hearts? We speak with the director of the 3D imaging group at Amrita, Professor Mahesh Kappanayil about this remarkable achievement of imaging in collaboration with surgery. DOI: 10.1016/j.jtcvs.2026.03.616

Imaging centers face serious legal exposure from contrast reactions—not from the reactions themselves, but from gaps in supervision and documentation. Discover why virtual models may offer stronger protection than on-site oversight and what your EHR templates are missing. Learn more at https://www.contrast-connect.com/blog-post/contrast-reaction-liability-exposure-supervision-model-risk-documentation-practices ContrastConnect City: Las Vegas Address: Las vegas Website: https://www.contrast-connect.com/

CMS made virtual contrast supervision permanent in 2026, but what does audit-ready documentation actually look like? We break down the technology requirements, physician availability standards, and emergency preparedness protocols imaging centers need to stay compliant. Learn more at https://www.contrast-connect.com/blog-post/virtual-contrast-supervision-audit-documentation-2026-cms-review-requirements-explained ContrastConnect City: Las Vegas Address: Las vegas Website: https://www.contrast-connect.com/

Preview for Later Today: Doug Messier describes NASA's innovative mission using robotic hoppers to survey the lunar South Pole, seeking water and potential sites for a future moon base through high-resolution imaging in the moon's environment.MAY 1952

Let's make it real: How do imaging tests change decisions at the bedside? Credit available for this activity expires: 5/28/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/episode-five-imaging-action-patient-cases-2026a1000dkq?ecd=bdc_podcast_libsyn_mscpedu

AUA2026: Focus on: Biomarkers, MRI and PSMA PET Imaging in Prostate Cancer Webcast CME Available: https://cme.auanet.org/URL/FOCUS262ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Critically appraise recent developments in imaging biomarkers and molecular diagnostics (e.g., genomic risk scores, liquid biopsy) and discuss how they complement MRI and PSMA PET in prostate cancer care. 2. Determine the optimal clinical scenarios (diagnostic, staging, recurrence, surveillance) in which PSMA PET/CT or PET/MRI adds value beyond conventional imaging. 3. Recognize potential pitfalls in PSMA PET interpretation — including false positives, false negatives, non–PSMA-expressing disease, and technical artifacts — and implement strategies to mitigate them. 4. Synthesize biomarker, MRI, and PSMA PET findings into a personalized management plan, including guiding biopsy, focal therapy, salvage therapy, or systemic treatments. 5. Select appropriate patients with radiorecurrent or organ-confined prostate cancer for advanced imaging and guide re-treatment decisions (e.g., salvage therapy, targeted radiotherapy). ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Blue Earth Diagnostics, Inc. Lantheus Medical Imaging

On this episode of The Agronomists, your host Lyndsey Smith is joined by Riley McConachie of the University of Guelph and Dr. Steve Shirtliffe of the University of Saskatchewan to discuss applications of drones and field imaging tech, including its use in plant breeding, field scouting, disease ID, seeding, and more! The Agronomists is brought... Read More

When a company proves it can see what others couldn't, the rules of drug development change overnight. Quantum BioPharma announced on May 18, 2026, that patient enrollment has reached the halfway mark in its collaborative imaging study with Massachusetts General Hospital, accompanied by encouraging preliminary results using a novel PET imaging technique capable of directly assessing demyelinated neurons with intact axons. The company's lead drug candidate, Lucid-MS, targets the underlying mechanism of multiple sclerosis—demyelination—rather than merely suppressing the immune system like most existing therapies. With an IND application submitted to the FDA on April 1, 2026, Quantum BioPharma is positioned at the intersection of breakthrough imaging science and first-in-class therapeutics.WHAT YOU NEED TO KNOWImaging Leap: PET scanning with [18F]3F4AP tracer provides up to 10x more accuracy than conventional MRI in measuring myelin damage and repair—potentially establishing a new FDA biomarker standard.Halfway Validated: First cohort successfully imaged at MGH showing robust signal in acute MS lesions; study completion expected within six months.First-in-Class: Lucid-MS targets PAD2 enzyme to prevent and reverse myelin breakdown—preclinical models demonstrated ability to help animals regain lost mobility.Commercial Scale: MS therapeutic market projected to exceed $38 billion by 2030, affecting 2.8 million patients worldwide with no current therapies addressing mobility restoration.STRATEGIC IMPLICATIONSThe MS treatment landscape is defined by what it cannot do. Virtually every approved therapy focuses on immune modulation—dampening the body's attack on its own myelin. But none address the underlying destruction happening to nerve fibers, and none restore lost mobility. Patients plateau on existing drugs, watching disease progression continue despite treatment. It's a multi-billion-dollar market built on managing symptoms, not reversing damage.Quantum BioPharma's approach disrupts that entire model. By targeting protein arginine deiminase 2 (PAD2)—the enzyme directly implicated in myelin degradation—Lucid-MS addresses neurodegeneration at its source. Phase 1 trials demonstrated a favorable safety profile. Preclinical models showed animals regaining the ability to walk. The oral formulation offers ease of administration versus injection-based competitors. And now, the MGH imaging partnership validates a tool that could measure myelin restoration in real time with unprecedented precision.CEO Zeeshan Saeed:“We've submitted the IND, we're at the halfway mark with MGH, and we're seeing preliminary imaging data that validates what we believed all along. This isn't about managing symptoms. It's about restoring what MS patients have lost. If this works—and we believe it will—we're talking about a fundamentally different standard of care.”INVESTOR TAKEAWAYQuantum BioPharma is executing on multiple fronts simultaneously: advancing a first-in-class therapeutic through FDA review, validating breakthrough imaging science with one of the world's premier hospitals, and preparing for Phase 2 initiation in a $38+ billion market with 2.8 million patients. The MGH study reaching its midpoint with encouraging preliminary results confirms the technical viability of precision myelin measurement. The IND submission positions Lucid-MS for near-term regulatory clarity. And the company's focus on demyelination—rather than immune suppression—addresses the core unmet need in MS: disease reversal, not just disease management. Quantum BioPharma offers investors exposure to a potentially transformative therapy at an inflection point in clinical and commercial validation.

Explore how virtual contrast supervision is reshaping imaging center budgets, with pricing from $45 to $150 per hour and potential cost reductions up to 70%. Learn about pricing models, implementation timelines, and why the radiologist shortage makes this a strategic necessity. Read more at https://www.contrast-connect.com/blog-post/virtual-contrast-supervision-cost-per-site-pricing-models-and-budget-planning ContrastConnect City: Las Vegas Address: Las vegas Website: https://www.contrast-connect.com/

Washington House Bill 2113 allows virtual physician supervision for IV contrast administration starting June 11, 2026, using real-time audiovisual technology. The law preserves patient safety requirements while offering imaging centers greater flexibility and reduced staffing costs. To learn more, visit https://www.contrast-connect.com/blog-post/washington-hb-2113-for-virtual-contrast-supervision-2026-requirements-changes-explained ContrastConnect City: Las Vegas Address: Las vegas Website: https://www.contrast-connect.com/

CMS made virtual contrast supervision permanent in 2026, requiring immediate physician availability and strict audit documentation. Learn what imaging centers must do now to stay compliant, avoid Medicare recoupment, and maintain patient safety under the new rule.https://www.contrast-connect.com/blog-post/cms-immediate-availability-definition-explained-meaning-distance-coverage-requirements-2026-update ContrastConnect City: Las Vegas Address: Las vegas Website: https://www.contrast-connect.com/

Dr Meghan Sak-Ocbina is a Doctor of Physical Therapy and Strength Coach and joins the show to share her expertise on:All the things your physical therapist wishes you knewThe issues within the system that make their role more difficultThe challenge between the cost of education and compensation in physical therapyTheir desire to give you the best care conflicting with the insurance modelWhy burnout in physical therapy is a potential problemWhat Meghan means by: “The problem with most rehab, it never makes it into training. We treat rehab and training like they're separate lanes, when they're meant to do the same thing — drive adaptation.”Why most people have at least one, if not a few, potential joint issues, and why this is normal and not necessarily a problemMeghan's response when a client was told by another clinician: “Because she doesn't do sports, she doesn't need to train power.”What Meghan means by: “Your injury isn't from what you're doing, it's from what you're not doing.”And much moreInstagram: @dr.megsi.dptCHAPTERS00:39 Insurance and Volume02:34 Cash Based PT05:34 Strength Coaching Edge08:32 PT Training Gaps11:33 Rehab and the Training Spectrum13:34 Pain and the Nervous System18:54 Patient Expectations21:04 Imaging and Surgery Myths23:44 Form Fear and Adaptation24:36 Outfunctioning Structure26:19 Imaging Fear and Nocebo27:46 Living With Wear and Tear30:22 Insurance Model Limits PT32:32 Burnout, Debt, and Paperwork35:55 Cash Based and Online Paths37:54 Choosing a PT Like Choosing a Haircut44:07 Rehab Meets Real Training47:27 Power Training For Everyone50:06 Aging, Capacity, and Injury Risk51:46 Where To Find MeghanSUPPORT THE SHOWIf this episode helped you better understand rehab, physical therapy, or injury management, you can support the show by:Subscribing and checking out more episodesSharing it on social media (tag me and I'll respond)Sending it to someone dealing with pain, rehab, or training frustrationsFOLLOW ANDREW COATESInstagram: @andrewcoatesfitnesshttps://www.andrewcoatesfitness.comPARTNERS AND RESOURCESRP Strength App (use code COATESRP)https://www.rpstrength.com/coatesJust Bite Me Meals (use code ANDREWCOATESFITNESS for 10% off)https://justbitememeals.comMacrosFirst – FREE Premium TrialDownload MacrosFirst and during setup select ANDREWKNKG Bags (15% off)https://www.knkg.com/Andrew59676Versa Grippshttps://www.versagripps.com/andrewcoatesTRAINHEROIC – FREE 90-Day Trialhttps://www.trainheroic.com/liftfreeReply to the email you receive (or email trials@trainheroic.com) and let them know Andrew sent you

Augmenting anatomy with disease activity! Summit Shah, MD MPH, explains to host, Raisa Amiruddin, MBBS, how visualizing disease activity through molecular imaging helps in solving diagnostic uncertainties. Explore how PET/MRI, brain mapping, targeted radiotracers, and theranostics are driving the shift towards personalized, precision medicine in pediatric patients. 

Imagine doing everything you love without getting tired or frustrated. Imaging being fully known and fully loved without any doubt or fear. That's a tiny peek into what Heaven looks like. Join Greg as he explores the question, “Could Heaven ever be boring?” ________________________________________________________________________________________________ Look for HOPE is Here: - at www.HOPEisHere.Today - on Facebook - https://www.facebook.com/HOPEisHereToday - on Instagram - https://www.instagram.com/hopeisherelex/ - on X (Twitter) - https://www.x.com/hopeisherelex - on TikTok - https://www.tiktok.com/@hopeisherelex - on YouTube - https://www.youtube.com/channel/UCtJ47I4w6atOHr7agGpOuvA Help us bring HOPE and encouragement to others: - by texting the word GIVE to 833-713-1591 - by visiting https://www.hopeisheretoday.org/donate   #Lexington #Kentucky #christianradio #JesusRadio #Jesus #WJMM #GregHorn #GregJHorn #suicideprevention #KentuckyRadio #HOPEisHere #Hope #HopeinJesus #FoodForThoughtFriday #MondayMotivation #FridayFeeling #Motivation #Inspiration #cupofHope #FYP #ForYouPage #SuicideAwareness

Dr. John Stenberg discusses the nuances of imaging in upper cervical chiropractic care, addressing common questions about when and why to use imaging, and how clinical decision-making varies based on experience, patient population, and personal philosophy.Chapters00:00 Navigating Imaging in Chiropractic Care09:31 Understanding Clinical Guidelines vs. Technique Standards18:49 Evaluating Patient Needs and Imaging Decisions25:26 Balancing Upper Cervical Techniques with Broader Chiropractic PracticesResources:@zenith_chiro on IGZenith Upper Cervical Chiropractic in Colorado Springs, CO

Host Cristina Fuss, MD, PhD, FSCCT is joined by guest-host Anjali Chelliah, MD, FSCCT as they discuss CT for Congenital Heart Disease through conversations with Jennifer Cohen, MD; Sunil Ghelani, MD, FSCCT and Kanwal Farooqi, MD.This episode will explore:Comparison of Single-source Cardiac CT and CMR Quantified Ventricular Volumes and Function in Congenital Heart Disease Rapid Growth of CT Utilization Compared to MRI and Echocardiography in Imaging for Congenital Heart Diseases: A Multicenter Analysis Association of Lower Noninvasive Fractional Flow Reserve Values with High Risk Anatomic Characteristics in Pediatric Patients with Anomalous Coronary Arteries Support the show

See what risk scores miss and apply imaging to guide real-world decisions. Credit available for this activity expires: 05/15/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/personalizing-risk-assessment-enhance-cardiovascular-2026a1000evy?ecd=bdc_podcast_libsyn_mscpedu

Dr. Justin Abbatemarco and Dr. Kait Nevel discuss tips and tricks for managing radiation necrosis in hospitals and outpatient settings.  Show transcript:  Dr. Justin Abbatemarco: Hello, and welcome. This is Justin Abbatemarco, and I just finished interviewing Kate Neville about radiation necrosis following radiosurgery. Kait is a neuro-oncologist at Indiana University. Kait, maybe we could just start with what this entity looks like and some tips and tricks on how we can manage in that hospital or in the outpatient setting when we were picking this up. Dr. Kait Nevel:  Yeah. Radiation necrosis can present in a variety of ways. People with radiation necrosis can be completely asymptomatic. In fact, most patients with radiation necrosis are asymptomatic. But symptoms can include things like headaches, seizures, and then focal neurologic deficits related to where the radiation necrosis is located. Imaging-wise, radiation necrosis typically looks like necrotic enhancing lesion as the name implies. Typically, we look at certain anatomical characteristics on standard MRI like vague enhancement along the edges, et cetera, but perfusion can be very helpful including cerebral blood volume, which is typically low in cases of radiation necrosis and high in cases of tumor progression. But this is a really big challenge in neuro-oncology, and differentiating radiographically between tumor and radiation injury. Dr. Justin Abbatemarco: I would encourage people to listen to podcast. We talked a little bit about medications, how to dose dexamethasone and others, and how we think through that. So please jump on and take a listen, and then join us back for the next Neurology Minute. We're going to talk about some evidence for supplement use in this disease. So Kait, thank you.  Dr. Kait Nevel: Great. Thank you.

What if the mammogram your doctor relies on is actually doing more harm than good, and a better option already exists? Dr. Cara Fuhrman, naturopathic doctor, Medical Director of Longevity RX, and daughter of nutritional science pioneer Dr. Joel Fuhrman, joins Integrative Cancer Solutions to break down the serious limitations of routine mammography, including staggering rates of overdiagnosis and overtreatment, and makes the case for QT Imaging as a radiation-free, far more accurate alternative. The conversation covers the three hormones silently fueling cancer growth, how everyday foods like white rice and animal protein accelerate tumor progression, and the anti-cancer power of cruciferous vegetables, flaxseeds, and raw garlic. If you want a more informed, proactive approach to breast cancer prevention, this episode delivers what your doctor may never tell you. Key Takeaways: 0:00 Introduction 0:32 Growing up with Dr. Joel Fuhrman and the nutritarian legacy 6:02 Layering herbs technology and nutrition to stop cancer 10:02 Mammogram overdiagnosis is harming more people than it helps 17:07 QT Imaging the radiation-free alternative to mammography 23:07 Why biopsies are overused and what to do instead 28:44 The three hormones silently fueling cancer growth 33:19 GBOMBS flaxseeds and garlic as everyday cancer medicine Resources: Dr. Cara's Instagram - https://www.instagram.com/drcarafuhrman/ Longevity RX -https://trylongevityrx.com/ Dr. Joel Fuhrman - https://www.drfuhrman.com Nordic Cochrane Centre - https://www.cochrane.org/ QT Imaging - https://www.qtimaging.com TerraSoul Superfoods - https://www.terrasoul.com Medical Disclaimer: This content is for educational purposes only and is not intended to diagnose, treat, cure, or replace professional medical advice. Always consult your physician or qualified healthcare provider regarding any medical condition or treatment decisions. ____________________________________RESOURCES FROM DR. KARLFELDT:

When it comes to our health, especially something as deeply personal as breast health, the decisions we make can feel heavy with uncertainty. We're often told what to do, when to do it, and to trust the process. But what happens when questions arise? World renowned, New York Times bestselling author, Joel Fuhrman, MD, wants us to understand the tools available to us. Traditional methods have changed to new emerging technologies that allow us to move from fear-based decisions to informed, intentional choices. Early detection is not just about finding something sooner; it's about understanding our options and feeling confident in the path we choose. Dr. Fuhrman will help us become truly informed and empowered in our health decisions! Now you can listen commercial free at your leisure…Click here and let's grow together: Joel Fuhrman, MD, Understanding Imaging & Early Detection If you love this podcast episode, share it with a friend. The Lillian McDermott Radio Show/Classroom ~ When You Need a Friend… PREMIERE:  Telegram, Facebook, YouTube, WhenYouNeedaFriend.com SUBSCRIBE, LIKE, & FOLLOW:    Facebook, Instagram, X, Website, Odysee, BitChute, YouTube! LISTEN:  Amazon Podcast, Apple Podcasts, YouTube Music, Spotify, Pandora, TuneIn, iHeartRadio! CALL or TEXT: 407-373-5959 “You can take a pill, or You can take Responsibility!” ®

In this episode of Data in Biotech, host Ross Katz sits down with Sadegh Salehi, Director of Research and Principal Scientist at Overjet, to explore what rigorous model evaluation actually looks like when the stakes are clinical.  Overjet builds FDA-cleared vision models that detect and quantify dental disease across billions of X-ray images from thousands of practices - a data problem with a staggering number of dimensions. Thirty-two teeth per adult patient, each with different morphology. Multiple image types capturing different anatomy. Fifteen to twenty sensor manufacturers producing perceptually distinct images, each with different contrast, resolution, and noise characteristics. And disease severity distributions ranging from barely visible early-stage decay to obvious pathology.  Sadegh walks through what it takes to evaluate models responsibly across all of those dimensions and discusses why aggregate metrics like F1 score can mask catastrophic failures on specific subgroups, how models find and exploit shortcuts in training data, and why the same flawed sampling that creates gaps in your training set also creates them in your test set.  He also traces Overjet's architectural evolution from over twenty narrow task-specific models to a single foundation model they call Unity, explains how treatment plan procedure codes provide a noisy but real production feedback signal, and describes how Overjet became one of the first companies to secure the FDA's Predetermined Change Control Plan (a framework that allows model updates without filing a new clearance each time.) What you'll learn in this episode:  >> Why aggregate evaluation metrics are insufficient for high-stakes medical AI  >> How models exploit shortcuts in training data: if all images from a rare sensor in the training set happen to be healthy, the model doesn't learn to read that sensor, it learns that the sensor means healthy, bypassing the visual task entirely and producing systematic false negatives in production >> How Overjet evolved from over twenty narrow, sensor-specific and indication-specific models into a single foundation model called Unity, using noisy labels generated by the small models as the training signal for a much larger backbone, then building independent prediction heads for each clinical indication on top of it >> Why the decision to keep prediction heads architecturally independent from one another was driven as much by FDA regulatory strategy as by modeling considerations >> How Overjet uses dental treatment plan procedure codes as a production monitoring signal Meet our guest: Sadegh Salehi is Director of Research and Principal Scientist at Overjet, where he leads the team responsible for building, evaluating, and deploying FDA-cleared vision models for dental disease detection and quantification.  Connect with Sadegh Salehi on LinkedIn: https://www.linkedin.com/in/sadegh-salehi/ About the host: Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Ross Katz on LinkedIn: https://www.linkedin.com/in/b-ross-katz/ Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode! Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. https://www.linkedin.com/company/corrdyn/

BUFFALO, NY – May 13, 2026 – A new #casereport was #published in Volume 17 of Oncotarget on May 4, 2026, titled “Laryngeal leiomyosarcoma: A rare case report and literature review.” The study was led by first author Bolat Shalabaev and corresponding author Zhuldyz Kuanysh, both from the National Research Oncology Center, Astana, Kazakhstan. In this report, the authors describe a rare case of high-grade laryngeal leiomyosarcoma (LLMS) in a 64-year-old man who presented with progressive dyspnea and hoarseness caused by a large supraglottic mass. Laryngeal leiomyosarcoma is an exceptionally uncommon malignant tumor of smooth muscle origin, with fewer than 70 cases reported worldwide since it was first described in 1939. Because most laryngeal malignancies are epithelial tumors such as squamous cell carcinoma, diagnosis of LLMS can be particularly challenging and requires extensive histopathological and immunohistochemical evaluation. Imaging studies revealed a heterogeneous laryngeal tumor causing near-complete obstruction of the airway. Histopathological analysis demonstrated high-grade spindle-cell proliferation with marked pleomorphism and pathological mitoses. Immunohistochemical testing showed strong expression of smooth muscle actin (SMA) and vimentin, while markers including CD34, myogenin, cytokeratins 5/6 and 7, and p40 were negative, supporting the diagnosis of high-grade pleomorphic leiomyosarcoma. The patient underwent extended laryngectomy with left neck dissection and formation of a permanent tracheostomy. Comprehensive staging with CT, MRI, and ultrasound showed no evidence of regional or distant metastases. Due to the tumor's aggressive pathological features—including a Ki-67 proliferation index reaching 60%—the multidisciplinary tumor board recommended adjuvant chemotherapy with doxorubicin and ifosfamide following surgery. “Complete surgical excision remains the cornerstone of therapy, while multidisciplinary-guided adjuvant treatment may benefit selected high-grade or high-risk patients.” Postoperative pathology confirmed a high-grade pleomorphic leiomyosarcoma classified as pT3N0M0 according to the AJCC 8th edition staging system. Importantly, surgical margins were negative, and no metastatic involvement was identified in the five examined lymph nodes. At the most recent follow-up, 12 months after surgery and completion of chemotherapy, the patient remained alive and free of recurrence or metastasis. The authors also reviewed recently published LLMS cases reported between 2021 and 2024. Their analysis confirmed persistent male predominance, frequent involvement of the glottic and supraglottic regions, and highly variable clinical outcomes ranging from long-term disease-free survival to rapid metastatic progression. The report further highlights the central role of immunohistochemistry in differentiating leiomyosarcoma from other spindle-cell neoplasms of the head and neck. Importantly, the study emphasizes that complete surgical resection with histologically negative margins remains the most important factor associated with favorable outcomes. While the role of chemotherapy in laryngeal leiomyosarcoma remains controversial, the authors note that individualized multidisciplinary treatment approaches may be particularly valuable in patients with high-grade or high-risk disease features. Overall, this report contributes important clinical insight into one of the rarest malignancies of the larynx. As the first documented case of laryngeal leiomyosarcoma reported from Central Asia, the study expands the limited global literature on this disease and underscores the importance of coordinated multidisciplinary care, detailed pathological evaluation, and long-term surveillance in optimizing patient outcomes. DOI - https://doi.org/10.18632/oncotarget.28862 Correspondence to - Zhuldyz Kuanysh - zhuldyzkuanysh@icloud.com Abstract video - https://www.youtube.com/watch?v=i3AoqIXo3Ys

Our U.S. Healthcare Analyst Erin Wright discusses how health tracking and preventive diagnostics could influence healthcare costs and different industries, from fitness to retail.Read more insights from Morgan Stanley.----- Transcript -----Welcome to Thoughts on the Market. I'm Erin Wright, Morgan Stanley's U.S. Healthcare Services Analyst. Today – the emergence of the self-directed patient and its implications. It's Tuesday, May 12th at 10am in New York. A blood test ordered from your phone. A wearable that tracks your sleep or nudges you to move, recover, hydrate, or rethink last night's dinner. Preventive health is moving out of the clinic and into everyday life. And that shift is becoming an investable theme. In essence, healthcare is moving from reactive to proactive. Instead of waiting for symptoms, more consumers are using lab tests, wearables, imaging, and digital tools to spot some these risks earlier. And this shift reaches well beyond healthcare. On our estimates, the U.S. spends about [$]3.4 trillion annually on chronic diseases, including lost economic productivity. About [$]1.4 trillion of 2024 spend was tied to preventable disease. So the big investment question is: can earlier detection and behavior change bend the cost curve? We think expanded preventive testing, screening, and monitoring can help avoid roughly [$]200 billion to [$]800 billion of U.S. healthcare spend by 2050. That assumes preventive testing reduces preventable disease costs by about 10% to 30% based on our analysis. Direct-to-consumer lab testing lets people order lab tests directly, often online, without starting with a traditional doctor visit. We see this as a roughly $4 billion U.S. market, which has more than doubled since 2021. And it's no longer niche. Our AlphaWise survey found that about 34% of respondents completed a voluntary wellness lab test in the past three years. Among users, the average was 3.2 tests, suggesting this is not just a one-time behavior. The most common test was a general health profile, used by about 45 percent of recent testers. Wearables are the other part of the story. Our survey found that 41 percent of respondents currently use a wearable or fitness device, while another 22 percent are interested in getting one. More importantly, people are acting on the data. 34 percent of wearable users today regularly change behaviors or decisions based on their device, and 52 percent even sometimes do so, based on our survey. That creates a feedback loop. A wearable might flag poor sleep. A lab test might show elevated glucose. A digital health tool might suggest changes to diet or exercise, or follow-up care. Over time, prevention starts to feel less like an annual event and more like a daily habit. The sector implications are broad. In healthcare, more testing may initially actually increase utilization as people follow up on results. But over time, earlier detection could obviously support lower-cost of care and better chronic disease management. That also aligns with value-based care, where providers and payers are rewarded for better outcomes and lower total costs, not just simply more services. In consumer sectors, better health tracking could shape food choices, reduce demand for some indulgent categories, and support products tied to hydration, lower sugar, protein, and functional benefits. Fitness may also benefit as gyms evolve from just workout destinations into broader wellness platforms, with recovery and coaching, and preventive health services layered in. Imaging is another emerging area, as screening shifts from reactive diagnostics toward earlier disease detection. Of course, there is some risk that these health tracking and consumer-driven diagnostics trends could still prove to be a wellness craze rather than the new normal. Out-of-pocket costs, privacy concerns, inconsistent interpretations, and limited repeat testing are all real issues. But consumers are clearly taking more control of their health and increasingly asking, “What can I learn before I get sick?” Thanks for listening. If you enjoy the show, please leave us a review wherever you listen and share Thoughts on the Market with a friend or colleague today.

Many veterans experience chronic pain even when imaging studies such as MRIs or X-rays appear normal. This can be frustrating and confusing, especially when symptoms are real but diagnostic tests do not provide clear answers.In this episode, we explore why imaging does not always correlate with pain in veterans. We discuss how the nervous system processes pain, why structural findings on imaging do not always explain symptoms, and how chronic stress, prior injuries, and nervous system sensitization can influence pain perception.Understanding the science behind pain can help explain why some veterans continue to experience symptoms even when traditional imaging studies appear normal.Topics CoveredWhy imaging findings don't always explain painHow the nervous system processes pain signalsThe difference between structural injury and pain perceptionWhy some imaging abnormalities cause no symptomsChronic pain and nervous system sensitization in veteransWhy pain can persist even after injuries heal

Send us Fan MailIn this PT Snacks episode, host Kasey introduces Baxter's nerve (the first branch of the lateral plantar nerve, also called the inferior/anterior calcaneal nerve) as an under-recognized source of medial plantar heel pain that can mimic plantar fasciitis and may account for up to 20% of chronic heel pain. We review the nerve's motor and sensory roles, common entrapment zones near the distal tarsal tunnel and medial calcaneal tuberosity, and typical presentation including burning neuropathic pain, possible paresthesia, focal tenderness, and potential abductor digiti minimi weakness or atrophy. This episode outlines key differentials, relevant imaging and testing findings (ultrasound, MRI, EMG/NCS), and a treatment progressions.00:00 Welcome to PT Snacks00:14 Baxters Nerve Overview02:14 Why It Matters03:03 Anatomy and Entrapment04:45 Symptoms and Differentials06:11 Imaging and Testing07:22 Clinical Exam Clues09:04 Treatment Options11:12 Key Takeaways12:58 Wrap Up and ContactNeed CEUs?Unlock unlimited online courses, live webinars, and certification-prep programs with MedBridge. You'll get thousands of accredited, evidence-based courses. Use code PTSNACKSPODCAST at checkout to save over $100. Student? Use code PTSNACKSPODCASTSTUDENTSupport the showStudying for the NPTE? Check out PT Final Exam — they've helped thousands of students pass with confidence. Use code PTSnacks at checkout for a discount.Stay Connected!Follow so you never miss an episode. Send your questions via email to ptsnackspodcast@gmail.comJoin the email list HERESupport the Show:Share the episode with someone who'd benefit.Contributing directly to the "support" link.Thanks for tuning in—your support makes this all possible!

Dr. Clint Sliker breaks down the critical imaging findings of cardiac and non-thoracic vascular trauma, highlighting how these rare but life-threatening injuries appear on CT. He shares practical insights to help radiologists recognize subtle signs, choose the right protocols, and maintain a high index of suspicion in high-stakes trauma cases. Imaging of Cardiac and NonaorticThoracic Vascular Trauma. Costenbader and Beheshtian et al. RadioGraphics 2026; 46(2):e250097. 

Most of medicine is built around snapshots. You feel something, you test for it, and by the time you find it, you're already behind. But what if the problem isn't the test—it's how we use it? In this episode, I sit down with physicist and imaging pioneer Dr. Daniel Sodickson, Chief Medical Scientist at Function Health and author of The Future of Seeing. We break down why tools like MRI are shifting from one-time scans to something far more powerful: tracking your health over time. Watch the full conversation on YouTube, or listen wherever you get your podcasts. In this episode, we cover: • Why waiting for symptoms puts you behind—and how to get ahead • What an MRI can reveal about your body that bloodwork can't • How tracking your health over time helps you catch problems sooner • Why having a baseline could change the way you make health decisions • What it means to shift from reacting to disease to actually predicting it When you stop looking at a single result and start looking at patterns, you can catch changes earlier, reduce false alarms, and better predict where your health is headed. View Show Notes From This Episode Get Free Weekly Health Tips from Dr. Hyman https://drhyman.com/pages/picks?utm_campaign=shownotes&utm_medium=banner&utm_source=podcast Sign Up for Dr. Hyman's Weekly Longevity Journal https://drhyman.com/pages/longevity?utm_campaign=shownotes&utm_medium=banner&utm_source=podcast Join the 10-Day Detox to Reset Your Health https://drhyman.com/pages/10-day-detox Join the Hyman Hive for Expert Support and Real Results https://drhyman.com/pages/hyman-hive This episode is brought to you by BON CHARGE, Maui Nui, Sunlighten, Paleovalley, Fatty15 and BIOptimizers. Head to boncharge.com/hyman and use code HYMAN for 15% off. Go to mauinuivenison.com/hyman to claim your free 6-pack of their Wild Axis Venison Jerky Sticks. Visit sunlighten.com and use code HYMAN to save up to $1600 today! Head to paleovalley.com/hyman to save 15% off your first order today. Head to fatty15.com/HYMAN today and use code HYMAN for 15% off your 90-day subscription Starter Kit. Head to bioptimizers.com/hyman and use promo code HYMAN at checkout to save 15%. (0:00) Introduction and overview of modern medical imaging (3:26) Discussion with Dr. Daniel K. Sodickson begins (3:45) Full body MRIs: Benefits, risks, and the inspiration behind "The Future of Seeing" (7:52) Extending senses and paradigm shifts in imaging technology (14:55) Longitudinal imaging and its benefits (19:17) Future of personalized health data and imaging technology (23:54) Addressing information overload and reducing false positives through AI (28:33) Cost, accessibility, and innovations in imaging techniques (32:00) Vision for ubiquitous and continuous health scanning (33:30) Imaging vs. blood work: Comprehensive health assessment (35:29) Real-life examples and early detection through imaging (39:27) Historical context and real-time health data collection (41:46) Who should get baseline MRIs and scan frequency (47:26) The everywhere scanner: Future implications and cancer detection (52:35) Medical intelligence and transforming health monitoring (57:47) Preventive measures, early detection, and course correction (1:00:30) Medical intelligence labs and the future of healthcare (1:03:32) Future of personal data-driven healthcare and closing remarks